23. SYSTEMATIC REVIEW OF THE COST - EFFECTIVENESS OF PEMBROLIZUMAB IN RECURRENT OR METASTATIC CERVICAL CANCER. YHCĐ 2025, 66 (CĐ8-NCKH). https://doi.org/10.52163/yhc.v66iCD8.2569.